Modality
Peptide
MOA
HPK1i
Target
MDM2
Pathway
Amyloid
IPF
Development Pipeline
Preclinical
Feb 2017
→ Dec 2027
PreclinicalCurrent
NCT03975297
574 pts·IPF
2017-08→TBD·Active
NCT06252865
2,347 pts·IPF
2017-02→2027-12·Completed
2,921 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-141.7y awayInterim· IPF
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Complet…
Preclinical
Active
Catalysts
Interim
2027-12-14 · 1.7y away
IPF
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03975297 | Preclinical | IPF | Active | 574 | CR |
| NCT06252865 | Preclinical | IPF | Completed | 2347 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 |